ClearPoint Neuro (NASDAQ:CLPT) Reaches New 12-Month High – Here’s What Happened

Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) hit a new 52-week high on Friday . The company traded as high as $25.75 and last traded at $25.05, with a volume of 1889067 shares changing hands. The stock had previously closed at $20.91.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CLPT shares. Stifel Nicolaus raised their price target on ClearPoint Neuro from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Weiss Ratings restated a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Saturday, September 27th. Finally, Wall Street Zen upgraded ClearPoint Neuro from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, ClearPoint Neuro currently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

ClearPoint Neuro Trading Up 9.3%

The business has a 50 day simple moving average of $12.63 and a 200-day simple moving average of $12.44. The company has a current ratio of 7.30, a quick ratio of 6.45 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $778.41 million, a price-to-earnings ratio of -33.80 and a beta of 1.19.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%.The business had revenue of $9.22 million during the quarter, compared to analyst estimates of $9.20 million. ClearPoint Neuro has set its FY 2025 guidance at EPS. On average, equities analysts predict that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

Hedge Funds Weigh In On ClearPoint Neuro

Several hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC lifted its stake in shares of ClearPoint Neuro by 156.3% in the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after purchasing an additional 452,043 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of ClearPoint Neuro by 107.3% in the 2nd quarter. Geode Capital Management LLC now owns 624,800 shares of the company’s stock valued at $7,461,000 after purchasing an additional 323,429 shares in the last quarter. Lane Generational LLC lifted its stake in shares of ClearPoint Neuro by 6.8% in the 2nd quarter. Lane Generational LLC now owns 258,427 shares of the company’s stock valued at $3,086,000 after purchasing an additional 16,382 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of ClearPoint Neuro by 98.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after purchasing an additional 127,823 shares in the last quarter. Finally, Conway Capital Management Inc. lifted its stake in shares of ClearPoint Neuro by 31.1% in the 1st quarter. Conway Capital Management Inc. now owns 211,325 shares of the company’s stock valued at $2,513,000 after purchasing an additional 50,100 shares in the last quarter. 30.08% of the stock is owned by institutional investors and hedge funds.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.